Prevent Diabetic Kidney Disease Among Egyptians

Not yet recruiting

• Conditions: Diabetes Mellitus Without Complication
• Interventions: Drug: Gliflozin

• Registration Number: NCT06071208
• Lead Sponsor: Fayoum University

Brief Summary

Study of the possibility to prevent the development of Diabetic kidney disease in type 2 diabetic patients

Detailed Description

Study of the possible role of the SGLT2 inhibitors to prevent the development of frank type2 DM among prediabetic candidates.

Study of the possible role of the SGLT2 inhibitors to prevent the development of diabetic complications, namely diabetic kidney disease, diabetic retinopathy and neuropathy.

Study Timeline

• Status Verified: 2023-10
• Study First Submitted: 2023-10-03
• Study First Submitted QC: 2023-10-03
• Study First Posted: 2023-10-06
• Last Update Submitted: 2023-10-06
• Last Update Posted: 2023-10-10
• Study Start: 2023-10-14
• Primary Completion: 2028-10-14
• Study Completion: 2028-12-14

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

• diabetics,prediabetics

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
cases of study	Gliflozin	Patients is diabetes whether recently discovered or long standing diabetes
controls of study	Gliflozin	prediabetics ,or patients with clinical manifestations of insulin resistance eg acanthosis negricans

Primary Outcome Measures

Name	Time	Method
prevention of diabetic complications	5 years	glomerular filtration rate will be measured at the beginning of the study and at the end